What are radiopharmaceuticals categorized under in the FDA schedules?

Radiopharmaceuticals are classified under Schedule C in the context of FDA schedules. This categorization is significant because it pertains to drugs that are used for diagnostic and therapeutic purposes, particularly in nuclear medicine. Schedule C drugs, including radiopharmaceuticals, require specific handling and regulatory compliance due to their radioactive properties and potential effects on health.

In Canada, the regulation surrounding radiopharmaceuticals is crucial for ensuring safety and efficacy, considering that these substances are administered for imaging or treating various medical conditions. Because they involve radioactive components, they must meet stringent guidelines for manufacturing, storage, and distribution to minimize risks to patients and healthcare professionals.

Thus, the classification under Schedule C not only underscores the therapeutic responsibilities associated with these substances but also indicates the level of control and oversight required in their use compared to other drug categories. This is essential for maintaining public health and safety in the administration of pharmaceutical care involving radiopharmaceuticals.